Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 342

1.

Dietary quercetin potentiates the antiproliferative effect of interferon-α in hepatocellular carcinoma cells through activation of JAK/STAT pathway signaling by inhibition of SHP2 phosphatase.

Igbe I, Shen XF, Jiao W, Qiang Z, Deng T, Li S, Liu WL, Liu HW, Zhang GL, Wang F.

Oncotarget. 2017 Nov 20;8(69):113734-113748. doi: 10.18632/oncotarget.22556. eCollection 2017 Dec 26.

2.

Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer.

Mishall KM, Beadnell TC, Kuenzi BM, Klimczak DM, Superti-Furga G, Rix U, Schweppe RE.

Oncotarget. 2017 Aug 24;8(61):103014-103031. doi: 10.18632/oncotarget.20488. eCollection 2017 Nov 28.

3.

Activated HGF-c-Met Axis in Head and Neck Cancer.

Arnold L, Enders J, Thomas SM.

Cancers (Basel). 2017 Dec 12;9(12). pii: E169. doi: 10.3390/cancers9120169. Review.

4.

Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha.

Olmez I, Love S, Xiao A, Manigat L, Randolph P, McKenna BD, Neal BP, Boroda S, Li M, Brenneman B, Abounader R, Floyd D, Lee J, Nakano I, Godlewski J, Bronisz A, Sulman EP, Mayo M, Gioeli D, Weber M, Harris TE, Purow B.

Neuro Oncol. 2018 Jan 22;20(2):192-202. doi: 10.1093/neuonc/nox119.

PMID:
29048560
5.

Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02.

Nghiemphu PL, Ebiana VA, Wen P, Gilbert M, Abrey LE, Lieberman F, DeAngelis LM, Robins HI, Yung WKA, Chang S, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, Prados M, Kuhn J, Cloughesy TF.

J Neurooncol. 2018 Jan;136(1):79-86. doi: 10.1007/s11060-017-2624-4. Epub 2017 Oct 7.

PMID:
28988377
6.

Lysosome trafficking is necessary for EGF-driven invasion and is regulated by p38 MAPK and Na+/H+ exchangers.

Dykes SS, Steffan JJ, Cardelli JA.

BMC Cancer. 2017 Oct 4;17(1):672. doi: 10.1186/s12885-017-3660-3.

7.

FGFR inhibitor, AZD4547, impedes the stemness of mammary epithelial cells in the premalignant tissues of MMTV-ErbB2 transgenic mice.

Zhao Q, Parris AB, Howard EW, Zhao M, Ma Z, Guo Z, Xing Y, Yang X.

Sci Rep. 2017 Sep 12;7(1):11306. doi: 10.1038/s41598-017-11751-7.

8.

Phospho-AXL is widely expressed in glioblastoma and associated with significant shorter overall survival.

Onken J, Vajkoczy P, Torka R, Hempt C, Patsouris V, Heppner FL, Radke J.

Oncotarget. 2017 Jun 13;8(31):50403-50414. doi: 10.18632/oncotarget.18468. eCollection 2017 Aug 1.

9.

EGFR and PDGFRA co-expression and heterodimerization in glioblastoma tumor sphere lines.

Chakravarty D, Pedraza AM, Cotari J, Liu AH, Punko D, Kokroo A, Huse JT, Altan-Bonnet G, Brennan CW.

Sci Rep. 2017 Aug 22;7(1):9043. doi: 10.1038/s41598-017-08940-9.

10.

EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise.

Westphal M, Maire CL, Lamszus K.

CNS Drugs. 2017 Sep;31(9):723-735. doi: 10.1007/s40263-017-0456-6.

11.

Internalized CD44s splice isoform attenuates EGFR degradation by targeting Rab7A.

Wang W, Zhang H, Liu S, Kim CK, Xu Y, Hurley LA, Nishikawa R, Nagane M, Hu B, Stegh AH, Cheng SY, Cheng C.

Proc Natl Acad Sci U S A. 2017 Aug 1;114(31):8366-8371. doi: 10.1073/pnas.1701289114. Epub 2017 Jul 17.

12.

A TNF-JNK-Axl-ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma.

Guo G, Gong K, Ali S, Ali N, Shallwani S, Hatanpaa KJ, Pan E, Mickey B, Burma S, Wang DH, Kesari S, Sarkaria JN, Zhao D, Habib AA.

Nat Neurosci. 2017 Aug;20(8):1074-1084. doi: 10.1038/nn.4584. Epub 2017 Jun 12.

13.

The small-molecule kinase inhibitor D11 counteracts 17-AAG-mediated up-regulation of HSP70 in brain cancer cells.

Schaefer S, Svenstrup TH, Guerra B.

PLoS One. 2017 May 18;12(5):e0177706. doi: 10.1371/journal.pone.0177706. eCollection 2017.

14.

Regulatory Mechanisms and Novel Therapeutic Targeting Strategies for Protein Tyrosine Phosphatases.

Yu ZH, Zhang ZY.

Chem Rev. 2018 Feb 14;118(3):1069-1091. doi: 10.1021/acs.chemrev.7b00105. Epub 2017 May 25.

15.

Foretinib Enhances the Radiosensitivity in Esophageal Squamous Cell Carcinoma by Inhibiting Phosphorylation of c-Met.

Chen GZ, Dai WS, Zhu HC, Song HM, Yang X, Wang YD, Min H, Lu Q, Liu S, Sun XC, Zeng XN.

J Cancer. 2017 Mar 12;8(6):983-992. doi: 10.7150/jca.18135. eCollection 2017.

16.

Metabolic Reprogramming in Glioma.

Strickland M, Stoll EA.

Front Cell Dev Biol. 2017 Apr 26;5:43. doi: 10.3389/fcell.2017.00043. eCollection 2017. Review.

17.

Insights into molecular therapy of glioma: current challenges and next generation blueprint.

Rajesh Y, Pal I, Banik P, Chakraborty S, Borkar SA, Dey G, Mukherjee A, Mandal M.

Acta Pharmacol Sin. 2017 May;38(5):591-613. doi: 10.1038/aps.2016.167. Epub 2017 Mar 20. Review.

PMID:
28317871
18.

Overcoming therapeutic resistance in glioblastoma: the way forward.

Osuka S, Van Meir EG.

J Clin Invest. 2017 Feb 1;127(2):415-426. doi: 10.1172/JCI89587. Epub 2017 Feb 1. Review.

19.

Disabled cell density sensing leads to dysregulated cholesterol synthesis in glioblastoma.

Kambach DM, Halim AS, Cauer AG, Sun Q, Tristan CA, Celiku O, Kesarwala AH, Shankavaram U, Batchelor E, Stommel JM.

Oncotarget. 2017 Feb 28;8(9):14860-14875. doi: 10.18632/oncotarget.14740.

20.

Supplemental Content

Support Center